New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.96 2.22 +1.67%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. (MRK) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Pharmaceutical 58,142 89.43%
Animal Health 6,354 9.77%
Other, not broken out 515 0.79%
Gross margin 74.80%
Operating margin 34.01%
Pre-tax margin 32.41%

Revenue by segment $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016
Pharmaceutical 58,142 57,400 53,583 52,005 42,754 36,610 34,100 37,689 35,390 35,151
Animal Health 6,354 5,877 5,625 5,550 5,568 4,703 4,393 4,212 3,875 3,478
Other Segments — — — — — 23 175 250 397 385
Other, not broken out 515 891 907 1,728 382 — 453 — 460 793
Revenue 65,011 64,168 60,115 59,283 48,704 41,518 39,121 42,294 40,122 39,807

Gross profit by segment $m, and margin

Revenue by region $m

Line FY2021 FY2020 FY2019
U.S. 22,425 19,588 18,420
Europe, Middle East and Africa 13,341 11,547 10,496
China 4,378 2,751 2,180
Japan 2,726 2,602 2,609
Asia Pacific (other than Japan and China) 2,407 2,113 2,126
Latin America 2,206 1,890 2,015
Other 1,221 1,027 1,275
Non-US 26,279 21,930 20,701
Revenue 48,704 41,518 39,121

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.